Last week, Insilico Medicine announced the start of Phase III trials for rentosertib, an oral TNIK inhibitor for idiopathic pulmonary fibrosis (IPF). At first glance, the news seems like just another biotechnology milestone among many. But it's unlike anything we've seen so far, and it's worth understanding why before we return to the discussion about the Brazilian program for radical innovation in healthcare. Rentosertib is the first molecule in history to reach a pivotal Ph

In recent years, Brazil has faced a persistent paradox: it produces ever-increasing amounts of science, but continues to transform little...

How to revive the cooperative model that can transform Brazil into a biotechnology powerhouse When I received the invitation in 2005 to...

The emergence of cutting-edge technologies, known as deeptechs, marks a new phase in global innovation. These technologies, which emerge...

Throughout my career as an executive, consultant, and entrepreneur in healthcare, I have always sought to connect science, innovation,...

Brazil’s biodiversity, widely recognized as one of the richest in the world, offers a window of opportunity for innovative health...